GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Short Percentage of Float

Nyrada (ASX:NYR) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Nyrada's Short Percentage of Float

For the Biotechnology subindustry, Nyrada's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyrada's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Nyrada's Short Percentage of Float falls into.


Nyrada (ASX:NYR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Short Percentage of Float
Comparable Companies
ASX:ANR ASX:HXL ASX:EX1 ASX:RGS ASX:NC6 ASX:ILA ASX:NSB ASX:1AD ASX:ZLD ASX:MEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Website
https://www.nyrada.com
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines